Wellington Shields Capital Management LLC Sells 5,700 Shares of Edwards Lifesciences Corporation $EW

Wellington Shields Capital Management LLC lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 10.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,031 shares of the medical research company’s stock after selling 5,700 shares during the period. Wellington Shields Capital Management LLC’s holdings in Edwards Lifesciences were worth $3,835,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Econ Financial Services Corp acquired a new position in Edwards Lifesciences in the second quarter valued at about $889,000. Allspring Global Investments Holdings LLC raised its holdings in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. Pacific Capital Partners Ltd bought a new stake in Edwards Lifesciences during the second quarter worth about $1,760,000. Czech National Bank increased its position in Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after buying an additional 7,917 shares during the last quarter. Finally, Mirova US LLC increased its position in Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after buying an additional 1,054,301 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 1.2%

Edwards Lifesciences stock opened at $82.48 on Monday. The stock has a market cap of $48.42 billion, a P/E ratio of 11.87, a PEG ratio of 3.97 and a beta of 1.05. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The firm’s fifty day moving average price is $77.58 and its 200-day moving average price is $76.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the firm earned $0.67 earnings per share. The company’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. National Bankshares set a $92.00 target price on Edwards Lifesciences in a research report on Friday. Mizuho increased their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday. Wells Fargo & Company upped their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. Robert W. Baird set a $83.00 target price on Edwards Lifesciences in a report on Friday. Finally, Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research note on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.24.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.